Home / Recalls / InvaGen Pharmaceuticals, Inc. / D-1124-2019

D-1124-2019 Class II Terminated

Recalled by InvaGen Pharmaceuticals, Inc. — Central Islip, NY

Recall Details

Product Type
Drugs
Report Date
April 24, 2019
Initiation Date
March 22, 2019
Termination Date
August 16, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
692538 vials

Product Description

Testosterone Cypionate Injection, USP, 200 mg/mL, For IM use only, 1 mL Vial, Single Dose, Rx Only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc., 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL 33323, NDC 69097-537-31.

Reason for Recall

Presence of Particulate Matter.

Distribution Pattern

Nationwide in the U.S.A.

Code Information

Lot #:GH80009, GH80010, GH80011 Exp 12/2019; GH80568, GH80575, GH80579, GH80580, GH80581, GH80582 Exp 4/2020; GH80646, GH80664, GH80665, GH80684, GH80699, GH80700, GH80701, GH80746, GH80761, GH80765, GH80777 Exp 05/2020; GH80801, GH80823, GH80828, GH80878 Exp 06/2020; GH80967, GH80968, GH81033, GH81034 Exp 07/2020; GH81042, GH81154 Exp 08/2020; GH81255, GH81256, GH81288, GH81289, GH81310 Exp 10/2020 and GH81311 Exp 10/2020

Other recalls by InvaGen Pharmaceuticals, Inc.

  • D-0220-2024 Class I — Vigabatrin for Oral Solution, USP 500 mg per packet, 50 packets per box, Rx Only (November 17, 2023)
  • D-1272-2020 Class III — Gabapentin Tablets USP, 600 mg, Rx Only, 500-count bottle, Manufactured for: Exe (May 14, 2020)
  • D-1454-2019 Class III — Testosterone Topical Solution 30mg of testosterone per pump actuation * each act (June 12, 2019)
  • D-1125-2019 Class II — Testosterone Cypionate Injection, USP, 1000 mg/10 mL (100 mg/mL), For intramuscu (March 22, 2019)
  • D-1123-2019 Class II — Testosterone Cypionate Injection, USP, 2000 mg/10 mL (200 mg/mL), For intramuscu (March 22, 2019)
  • D-0012-2019 Class III — Amlodipine Besylate USP 10 mg Tablets, 1000-count bottles, Rx Only, Manufactured (October 3, 2018)
  • D-1212-2018 Class III — Bupropion Hydrochloride ER Tablets, USP 150 mg, packaged in a) 90-count bottle ( (September 6, 2018)
  • D-0618-2018 Class III — buPROPion HCl Extended-Release Tablets, USP (SR), 100 mg, 60 count bottles, Rx (March 15, 2018)
  • D-0619-2018 Class III — buPROPion HCl Extended-Release Tablets, USP (SR), 150 mg ,a) 60 count (NDC 690 (March 15, 2018)
  • D-0698-2018 Class III — Decitabine for Injection, 50mg per vial, Rx only, Manufactured by: Cipla Ltd., V (March 5, 2018)